Quantexa wraps up $175m Series F investment round
Quantexa, a UK-based AI, data, and analytics software company, has completed its $175m (£136.5m) Series F investment round.
The round was led by Teachers' Venture Growth (TVG), part of the Ontario Teachers' Pension Plan.
Existing investors, including British Patient Capital, also participated in the round.
The latest funding round values the British technology company at $2.6bn.
Quantexa founder and CEO Vishal Marria said: "This latest investment reflects investors' embracing our vision and committing to join our journey as we accelerate innovation, platform deployments, and amplify the value we deliver to clients and the broader ecosystem.
'With the continued support of our investors, now including TVG, we are poised to push the boundaries of AI by harnessing the power of trusted data, reinforcing our leadership in this rapidly evolving landscape.'
The company said it plans to use the funds to accelerate platform innovation, enhance client experiences, and forge new partnerships and alliances.
The funding will also be used by the company to expand its presence in North America, and explore 'strategic' mergers and acquisitions.
As part of the investment, Ara Yeromian, managing director at TVG, will join Quantexa's board of directors, which also includes representatives from other investors such as Warburg Pincus, Dawn Capital, BNY, Evolution Equity Partners, AlbionVC, and HSBC.
Under the agreement, TVG will offer its expertise in scaling high-growth AI and software companies, along with its extensive network, to support Quantexa's international expansion and growth objectives.
TVG EMEA senior managing director and head Avid Larizadeh Duggan said: 'Businesses today need to build trusted data foundations to enable AI-enhanced decision making, to drive real world impact. Quantexa is revolutionising how they do this.
'At TVG, we invest in high-growth, game-changing companies, led by visionary leaders making a global difference. Quantexa's impressive track record, expanding customer base, and bold approach to data and AI innovation make it a natural fit for our portfolio.'
"Quantexa wraps up $175m Series F investment round" was originally created and published by Verdict, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
$1.2 bN Human Microbiome-based Drugs and Diagnostics Global Markets, 2022-2024 & 2025-2030
The human microbiome-based drugs and diagnostics market is projected to grow from $393.4M in 2025 to $1.2B by 2030, at a CAGR of 25.6%. Key players include Ferring, Nestlé Health Science, and Vedanta Biosciences. The report covers market trends, competitive landscape, and ESG developments. Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Human Microbiome-based Drugs and Diagnostics: Global Markets" report has been added to global market for human microbiome-based drugs and diagnostics is expected to grow from $393.4 million in 2025 to reach $1.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 25.6% from 2025 through 2030. The report discusses emerging technologies and analyzes the competitive landscape, providing the ranking/market shares of leading companies in the market. It also includes a chapter on environmental, social and corporate governance (ESG) microbiome-based drugs and diagnostics are novel approaches to tackling difficult-to-treat diseases. The growing understanding of the human microbiome can be leveraged to fill the gaps in conventional treatment options. A wide range of scientific studies have demonstrated the role of microbiomes in the pathogenesis of various diseases. The microbiome field is also witnessing an increased level of investments from the private and public sectors. Future opportunities in the market lie in exploring microbiomes in other body parts, such as lungs, and developing microbiome-based drugs as combination therapies. Leading companies in the market for human microbiome-based drugs and diagnostics include Ferring, Nestle Health Science (Seres Therapeutics), BiomeBank, Genetic Analysis AS and Vedanta Scope 55 data tables and 51 additional tables Analyses of the trends in global markets for human microbiome-based drugs and diagnostics, with revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030 Estimates of the size and revenue prospects for the global market, along with a market share analysis by type, drug route of administration, diagnostics product type, application, end user, and region Facts and figures pertaining to market dynamics, opportunities and deterrents, technological advances, regulations, and the impacts of macroeconomic variables Review of the prevalence of infectious diseases, metabolic disorders and chronic ailments An assessment of current products, clinical trials and identification of new potential markets for novel products and assay development Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes An analysis of the key patent grants and recently published patents Analysis of the industry structure and value chain, and the competitive landscape, including companies' market shares, strategic alliances, M&A activity, venture fundings and investment outlook Profiles of the leading companies, including Ferring Pharmaceuticals, Nestle Health Science, BiomeBank, Genetic Analysis AS, and Vedanta Biosciences Inc. Companies Featured BiomeBank EnteroBiotix Ltd. Enterome Ferring Genetic Analysis Illumina Inc. Microbiome Insights Microbiotica Nestle Health Science Oxford Nanopore Technologies plc PacBio SFA Therapeutics Inc. Thermo Fisher Scientific Inc. Vedanta Biosciences Inc. Key Topics Covered: Chapter 1 Executive Summary Market Outlook Scope of Report Market Summary Market Dynamics Emerging Technologies Analysis by Segment Regional Analysis Conclusion Chapter 2 Market Overview Overview and Market Definition Different Microbiomes in Humans Microbiome, Human Health and Disease Technologies Aiding Microbiome Research Culturing and Cultivation Strategies for the Development of Microbiome Therapeutics Additive Microbiome Therapy Modulatory Microbiome Therapy Analysis of Macroeconomic Factors Geopolitical Factors Inflation and Currency Exchange Fluctuations Porter's Five Forces Analysis Chapter 3 Market Dynamics Takeaways Market Drivers Growing Evidence of Microbiome-disease Correlation Microbiome-based Diagnostics for Disease Prevention and Monitoring Market Restraints Challenges in Clinical Trial Design Lack of Established Regulatory Frameworks High Costs of Microbiome Therapeutics Market Opportunities Direct-to-Consumer Microbiome Testing Drugs and Diagnostics for Lung and Skin Microbiomes Chapter 4 Regulatory Landscape Regulatory Aspects North America Europe Asia-Pacific Chapter 5 Emerging Technologies Takeaways Emerging Technologies Microbial Ecosystem Therapeutics Metatranscriptome Sequencing Genetically Modified Microbiome Therapeutics Combination and Adjuvant Therapies with Microbiome-based Drugs Novel Preclinical Models Chapter 6 Market Segmentation Analysis Segmentation Breakdown Market Analysis by Type Microbiome-based Drugs Market Analysis by Application Infectious Diseases GI Disorders Metabolic Disorders Cancer Other Diseases Market Analysis by End User Hospitals and Clinics Research Institutions Pharmaceutical Companies Geographic Breakdown Market Analysis by Region North America Europe Asia-Pacific South America Middle East and Africa Chapter 7 Competitive Intelligence Takeaways Company Share Analysis Competitive Analysis Venture Funding and Investment Landscape Recent Developments Chapter 8 Sustainability in the Human Microbiome-based Drugs and Diagnostics Industry: An ESG Perspective Introduction to ESG ESG Risk Ratings Concluding Remarks Chapter 9 Appendix For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
27 minutes ago
- Yahoo
Citigroup to axe around 3,500 tech roles in China
Citigroup is trimming its workforce size by approximately 3,500 at two of its technology centres in China, reported Reuters. The aim is to consolidate and streamline the bank's global technology operations to enhance its risk and data management systems. The staffing reductions will affect the China Citi Solution Centres in Shanghai and Dalian, with the bank planning to complete the process by the start of the fourth quarter of this year, the news agency said citing a statement by Citi. The jobs being cut are predominantly full-time positions, a source privy to the development disclosed. Some of the jobs from these centres would be relocated to other technology hubs within the company, although the specifics regarding the number of jobs or their destinations were not provided. This announcement follows last month's report, which indicated that Citigroup was reducing around 200 information technology contractor roles in China. In March, the bank communicated internally its strategy to decrease its reliance on IT contractors and to increase its in-house IT staff, in response to penalties imposed by regulators concerning data governance and control shortcomings. The downsizing in China is part of Citigroup's global restructuring plan, which has also seen the bank scaling back operations in the US, Indonesia, the Philippines, and Poland. The China-based service and technology unit is tasked with delivering financial technology and operations services to support Citigroup's global business operations. Citigroup is currently in the process of establishing a securities unit in China, still maintain the regional presence. Post-reduction, Citigroup's staff count in China is expected to be around 2,000, which includes several hundred employees within the technology division. Citi Japan, Asia North and Australia banking head Marc Luet was quoted by Reuters as saying: "Citi continues to pursue the establishment of a wholly owned securities and futures company in China." "Citigroup to axe around 3,500 tech roles in China " was originally created and published by Retail Banker International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Wall Street Journal
37 minutes ago
- Wall Street Journal
U.K. Fintech Firm Wise to Move Main Listing to U.S.
LONDON—British payments company Wise WISE 6.46%increase; green up pointing triangle said it plans to move its main stock listing to the U.S., in the latest blow to European markets that have experienced a wave of defections. The details
